Fresh Tracks Therapeutics has hit pause on its drug development pipeline to save capital resources and figure out its exit strategy.
The research interruption includes foregoing part two of a Phase I trial investigating its lead asset FRTX-02 in atopic dermatitis. The pause will allow the Boulder, CO biotech to plan what’s next for the asset based on positive results released in March from the trial’s part-one portion.
The Phase I trial was designed to study single and multiple ascending FRTX-02 doses first in healthy volunteers, with part two intended to enroll moderate-to-severe atopic dermatitis subjects. FRTX-02 is under consideration in autoimmune diseases, including atopic dermatitis, rheumatoid arthritis and type 1 diabetes, the company website says.
“The outcome of our strategic options initiative will dictate the company’s future path including to what extent the current pipeline continues to be developed,” the company wrote…
Click here to view original post
